全文获取类型
收费全文 | 660篇 |
免费 | 53篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 54篇 |
妇产科学 | 49篇 |
基础医学 | 105篇 |
口腔科学 | 10篇 |
临床医学 | 57篇 |
内科学 | 152篇 |
皮肤病学 | 9篇 |
神经病学 | 36篇 |
特种医学 | 33篇 |
外科学 | 55篇 |
综合类 | 5篇 |
预防医学 | 34篇 |
眼科学 | 3篇 |
药学 | 78篇 |
中国医学 | 3篇 |
肿瘤学 | 29篇 |
出版年
2021年 | 21篇 |
2020年 | 5篇 |
2019年 | 11篇 |
2018年 | 17篇 |
2017年 | 8篇 |
2016年 | 8篇 |
2015年 | 10篇 |
2014年 | 5篇 |
2013年 | 11篇 |
2012年 | 16篇 |
2011年 | 26篇 |
2010年 | 21篇 |
2009年 | 28篇 |
2008年 | 18篇 |
2007年 | 20篇 |
2006年 | 24篇 |
2005年 | 22篇 |
2004年 | 36篇 |
2003年 | 15篇 |
2002年 | 23篇 |
2001年 | 18篇 |
2000年 | 13篇 |
1999年 | 22篇 |
1998年 | 17篇 |
1997年 | 10篇 |
1996年 | 18篇 |
1995年 | 10篇 |
1994年 | 17篇 |
1993年 | 13篇 |
1992年 | 11篇 |
1991年 | 11篇 |
1990年 | 17篇 |
1989年 | 17篇 |
1988年 | 18篇 |
1987年 | 10篇 |
1986年 | 18篇 |
1985年 | 12篇 |
1984年 | 13篇 |
1983年 | 11篇 |
1982年 | 6篇 |
1981年 | 5篇 |
1980年 | 8篇 |
1979年 | 10篇 |
1978年 | 6篇 |
1977年 | 5篇 |
1976年 | 9篇 |
1975年 | 5篇 |
1972年 | 5篇 |
1971年 | 5篇 |
1968年 | 4篇 |
排序方式: 共有713条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
5.
6.
LEE JS IM HH JUNG Y JUNG IS JANG JY CHUN YK CHO YD KIM JO CHO JY KIM YS SHIM CS & KIM BS 《Neurogastroenterology and motility》2006,18(6):493-494
Background: Recent development of extracorporeal magnetic stimulation (ECMS) which uses current‐changing magnetic fields allows the induction of electrical stimulation in the desired deep tissue. Recent study showed the sacral nerve stimulation reduces corticoanal excitability that may play a functional role in anal continence mechanisms. Preliminary study shows that ECMS of sacral nerve can modify pelvic floor function and expel rectal balloon in patients with pelvic floor dyssynergia (PFD). Aims: To evaluate the effect of ECMS compared with biofeedback therapy (BF) in patients with PFD. Methods and Materials: Thirty‐eight patients who fulfilled Rome II criteria for PFD by colon transit time and anorectal function tests, were randomly treated with 8 sessions of ECMS (2/weeks; n = 19) at prone position or BF (2/weeks; n = 19) at sitting position. Stimulation parameters were set at 50–80% of maximum intensity, 10 and 50 Hz frequency, 3 s burst length with 3 and 6 s off using arm‐typed stimulator (BioCom‐1000, Mcube Co., Korea). Symptom scores for constipation with/without anorectal function test were repeatedly measured after each treatment. Response was defined as 50% or more decreased symptom score after treatment (partial response: 30–50%, poor: <30%). Results: Fifteen patients (age 49.1 ± 13.4 years, mean ± SD; 4 men) completed 8 session of BF and 14 patients (54.5 ± 17.6 years, 3 men) completed 8 session of ECMS. Four patients of BF group discontinued treatment due to unsatisfactory therapeutic effect (n = 1) and withdrew consent (n = 3) and 5 patients of ECMS group discontinued treatment because of same reasons (n = 1, 4). Total symptom scores were significantly decreased after treatment of 8 session in both treatment groups (13.4 ± 6.6 vs. 4.3 ± 4.0 for BF, p = 0.009; 14.9 ± 5.6 vs. 3.4 ± 4.0 for ECMS, p < 0.001). Bowel movements per week were also significantly increased after treatment in both groups (median 2 vs. 7 for BF, p = 0.035; median 2 vs. 7 for ECMS, p = 0.008). Thirteen out of 15 patients showed response in BF group and 12 out of 14 showed good response in ECMS group. No adverse effects in both groups. Conclusions: ECMS is as effective as BF for the treatment of PFD. Long‐term effect of ECMS for the patients with pelvic floor dyssynergia need to be evaluated in the near future. 相似文献
7.
S. A. Shah M. S. Cattral I. D. McGilvray L. D. Adcock G. Gallagher R. Smith L. B. Lilly N. Girgrah P. D. Greig G. A. Levy D. R. Grant 《American journal of transplantation》2007,7(1):142-150
Many centers are reluctant to use older donors (>44 years) for adult right-lobe living donor liver transplantation (RLDLT) due to concerns about possible increased morbidity in donors and poorer outcomes in recipients. Since 2000, 130 adult RLDLTs have been performed at our institution. Recipients were divided into those who received a right lobe graft from a donor ≤age 44 (n = 89, 68%; median age 30) and those who received a liver graft from a donor age >44 (n = 41, 32%; mean age 52). The two donor and recipient populations had similar demographic and operative profiles. With a median follow-up of 29 months, the severity and number of complications in older donors were similar to those in younger donors. No living donor died. Older donor allografts had initial allograft dysfunction compared to younger donors. Complication rates were similar among recipients in both groups but there was a higher bile duct stricture rate with older donor grafts (27% vs. 12%; p = 0.04). One-year recipient graft survival was 86% for older donors and 85% for younger donors (p = 0.95). Early experience with the use of selected older adults (>44 years) for RLDLT is encouraging, but may be associated with a higher rate of biliary complications in the recipient. 相似文献
8.
9.
D K Benjamin R Schelonka R White H P Holley E Bifano J Cummings K Adcock D Kaufman B Puppala P Riedel B Hall J White C M Cotton 《Journal of perinatology》2006,26(5):290-295
OBJECTIVES: Very low birth weight (VLBW) infants are vulnerable to nosocomial infections and subsequent morbidity; including infections caused by Staphylococcus aureus: 85% of nosocomial S. aureus infections are caused by capsular polysaccharide (CPS) types 5 and 8. Altastaph is a polyclonal investigational human immunoglobulin G (IgG) with high levels of opsonizing S. aureus CPS types 5 and 8 IgG. METHODS: A Phase 2 clinical trial to assess the safety and kinetics of Altastaph in VLBW infants. Neonates in this multicenter study were randomized to receive two identical 20 ml/kg i.v. infusions of either 0.45% NaCl placebo or 1000 mg Altastaph/kg. Each infant was followed for 28 days after the second infusion or until discharge. Serum S. aureus CPS types 5 and 8 IgG levels were measured preinfusion and at various times after each infusion. RESULTS: Of 206 neonates, 158 received both infusions. Adverse events were similar in the two treatment groups. Six subjects (3% in each group) discontinued owing to an adverse event. Geometric mean anti-type 5 IgG levels were 402 and 642 mcg/ml 1 day following infusion of the first (day 0) and Second (day 14) doses, respectively, in neonates < or =1000 g and slightly higher in neonates 1001 to 1500 g. Trough levels before second infusion were 188 mcg/ml. Type 8 IgG levels were similar. Geometric mean IgG levels among placebo recipients were consistently <2 and <5 mcg/ml for types 5 and 8 in both weight groups. Three episodes of S. aureus bacteremia occurred in each arm. CONCLUSIONS: Infusion of Altastaph in VLBW neonates resulted in high levels of specific S. aureus types 5 and 8 CPS IgG. The administration of this anti-staphylococcal hyperimmune globulin was well tolerated in this population. 相似文献
10.
The vascularity of 49 renal masses (26 malignant and 23 benign lesions) was investigated with duplex Doppler ultrasound. Doppler signals obtained at the margins of renal masses were defined as "tumor signals" when the Doppler-shifted frequency of the lesion exceeded the frequency shift in the ipsilateral main renal artery. These exceeded 2.5 kHz with a 3-MHz insonating frequency. Among the 26 renal masses that subsequently proved to be malignant, tumor signals were obtained in 15 of 18 (83%) untreated renal cell carcinomas, in three of four Wilms tumors, and in two patients with metastases to the kidney, but not in the one patient with lymphoma. None of the 23 benign renal masses demonstrated tumor signals. Tumor vascularity in malignant lesions gives rise to abnormal, high-velocity, Doppler-shifted signals that can help in the differential diagnosis of renal masses. 相似文献